Most LBO explainers stop at "debt amplifies returns." That is true in the same way "cars have wheels" is true. It is a fact that tells you nothing about how the thing actually works. This walkthrough takes a synthetic but deliberately realistic mid-market deal — a $2 billion take-private of a specialty chemicals distributor — and traces every number from sourcing to exit. The goal is not to glorify leverage, but to show where the return actually comes from, and how quickly a deal can go from a winner to a cautionary tale.
In a well-structured LBO, roughly half of the sponsor's equity return typically comes from debt paydown during the hold, with the remainder split between EBITDA growth and multiple expansion. When sponsors talk about "operational value creation," they are usually describing the first two — because they cannot count on the third.
The Target
ChemDist Corp is a fictional but archetypal specialty chemicals distributor. $800 million in revenue, $120 million in EBITDA, growing at 4% organically with an additional 2-3% per year from small tuck-in acquisitions. Customers are industrial manufacturers in the US midwest and the southeast. Margins are stable because the business is primarily a logistics and credit intermediary rather than a pure product reseller. Capital intensity is modest — about 2% of sales in maintenance capex and a similar figure in working capital as the business grows.
Why is it a good LBO candidate? Because the cash flow is predictable, the customer base is diversified, the end markets are non-cyclical enough to sustain debt service through a mild downturn, and the asset base supports substantial secured borrowing. A business like this can typically carry 5.5-6.5x leverage on day one.
The seller is a family trust that has held the business for three decades. They want liquidity, they do not want to run an IPO process, and they want speed. These are the conditions under which mid-market sponsors earn their fees: proprietary sourcing and execution certainty beat price in a competitive auction.
Sources and Uses
The deal is priced at 11.0x trailing EBITDA, or $1,320 million enterprise value. That valuation is a touch below the median for specialty distributors in the quarter, which is deliberate — the sponsor is pricing to win, but not by much. Including refinancing of $180 million of existing debt and $30 million in advisor fees, the total use of capital is $1,530 million.
USES $M
Purchase equity 1,320
Refinance existing debt 180
Fees (advisory, financing) 30
Minimum cash 20
Total uses 1,530
SOURCES $M
Sponsor equity 460 (30.1%)
Seller rollover 50 (3.3%)
Revolver (undrawn) 0
Term Loan B 720 (47.1%) 6.0x EBITDA
Unsecured notes 300 (19.6%) 2.5x EBITDA (incremental)
Total sources 1,530
Total leverage is 8.5x EBITDA. That is high — too high for a traditional LBO in the 2010s, but in line with what the 2024-2026 credit market has been willing to underwrite for predictable cash-flow businesses. The secured portion (TLB) is 6.0x, and the unsecured tranche covers the gap to close the deal without a punitive equity check.
Capital structure at close
$M sourcesThe Debt Structure
The term loan is a seven-year TLB at SOFR + 425, with a 1% Libor floor and a 101 soft call in year one. Amortization is 1% annually with the balance due at maturity. The unsecured notes are an 8-year tranche at 9.75% fixed, non-call for three years. The revolver is a $100 million facility at SOFR + 375, undrawn at close, there as a liquidity backstop.
Why this structure? Because the secured lenders need a covenant package that gives them confidence, and the unsecured lenders need a coupon high enough to compensate for their subordination. The blended cost of debt at close is roughly 9.4%. That is expensive by historical standards. It would have been 5.5% in 2021. The difference is the cost of entry: higher rates mean the sponsor has to generate more operational improvement to hit the same return.
The Base Case Projection
The sponsor models a five-year hold. Revenue grows from $800 million to $1,050 million, a blend of 4% organic growth and three tuck-in acquisitions at 7x EBITDA each. EBITDA margins expand modestly, from 15.0% to 16.2%, driven by procurement consolidation and the absorption of acquisition synergies. Exit EBITDA is $170 million.
# Base case projection
years = [0, 1, 2, 3, 4, 5]
revenue = [800, 848, 904, 952, 1002, 1050]
ebitda_margin = [0.150, 0.152, 0.155, 0.158, 0.160, 0.162]
ebitda = [r * m for r, m in zip(revenue, ebitda_margin)]
# [120, 129, 140, 150, 160, 170]
# Free cash flow after interest and taxes
# Cash sweep on TLB paydown
Free cash flow after interest, taxes, capex, and working capital needs averages $55 million per year in the early years and climbs to $80 million by year five as EBITDA grows and interest expense declines. That cash is swept against the TLB principal under a 75% excess cash flow sweep through year three, reverting to 50% in years four and five.
The Debt Schedule
This is the part most LBO explainers skip, and it is where the return actually lives. Tracking the debt balance year by year shows how the equity becomes more valuable without anything changing about the enterprise value.
Year TLB Begin Mand.Amort Sweep TLB End Unsec Notes
0 720 - - 720 300
1 720 7.2 35 678 300
2 678 7.2 45 626 300
3 626 7.2 55 564 300
4 564 7.2 40 517 300
5 517 7.2 30 480 300
Total debt at close: 1,020
Total debt at exit: 780
Debt paydown: 240
That $240 million of debt paydown accrues directly to the equity. At exit, the net debt is lower, so the equity value of the same enterprise has grown by roughly that amount. This is the first lever.
The Exit
Sponsor models an exit at 10.5x EBITDA at the end of year five — slightly below entry to be conservative about multiple compression. Exit enterprise value is $1,785 million. Subtracting net debt of $760 million (after $20 million of cash on the balance sheet) gives an equity value of $1,025 million.
The sponsor contributed $460 million of equity at close. The equity exit value of $1,025 million represents a gross money-on-money (MOIC) of 2.23x over five years, or a gross IRR of approximately 17.4%. After a typical 2-and-20 fee structure and carry waterfall, the LP net IRR lands around 13-14%.
Where the Return Comes From
Attribution breaks the return into three buckets: EBITDA growth, multiple expansion, and debt paydown.
Source Contribution to equity value
EBITDA growth ($170 - $120) × 10.5x = $525M
Multiple expansion $120 × (10.5 - 11.0) = -$60M (headwind)
Debt paydown $240M
Total value creation $705M
With $460 million of equity at entry and $1,025 million at exit, the total delta is $565 million. The attribution above sums to $705 million because the sources overlap — debt paydown and EBITDA growth interact. But the qualitative point stands: with a modest multiple compression, the deal still returns 2.2x because EBITDA growth and debt paydown do the heavy lifting.
Equity value attribution
$M, base caseIf the sponsor had assumed flat multiples, the MOIC would have been 2.4x. If they had assumed multiple expansion to 12x (a stretch but not absurd), it would have been 2.6x. And if EBITDA growth had fallen short — say it hit $150 million instead of $170 million — the MOIC would have dropped to 1.9x even with flat multiples.
The sensitivity table is where LBO deals live or die. A deal that needs both EBITDA growth AND multiple expansion to clear the hurdle rate is a bad deal. A deal that can survive flat multiples AND reasonable-case EBITDA growth is a good deal.
The Failure Modes
Every LBO post-mortem I have read tells the same three stories. First: overpaying at entry. A deal bought at 12.5x that exits at 10.5x has to run uphill from day one. Second: underestimating working capital. Growing a distribution business eats cash faster than the model assumes, and that cash comes out of debt paydown, which eats the return. Third: pretending the downside case does not exist. A 2008 comes along, EBITDA drops 25%, the covenants get tight, and the sponsor has to inject equity to keep the lenders calm. That equity dilutes the return even if the business recovers.
The ChemDist model above survives a 15% EBITDA drop in year two — covenants stay clean because the structure is loose enough, and the sweep just slows. It does not survive a 25% drop, because the unsecured coupon eats the cash cushion and the sponsor has to either refinance at worse terms or amend and extend. Knowing which of these outcomes is more likely is what separates good sponsors from lucky ones.
Final Notes
This walkthrough is synthetic, but every number is in the realistic range for 2024-2026 mid-market specialty distribution deals. The structure, the pricing, the sensitivities, and the failure modes are what you would actually see in the deal team's investment committee memo. LBOs are not magic. They are financial engineering applied to a real operating business, and the return is the product of a few levers: entry price, growth, cost of debt, debt paydown, and exit multiple. Pull any one of them in the wrong direction and the deal dies. Pull them all in the right direction and you get 2.5x. That is the entire game.
Equity.FinanceContinue reading
Unlock the rest of this article, the full premium archive, and advanced models.
- Full premium research archive
- Advanced models & tools
- Early access to new research
Already a member? Sign in